InvestorsHub Logo
Followers 4
Posts 2010
Boards Moderated 0
Alias Born 09/19/2008

Re: Sagemen post# 2435

Saturday, 04/04/2009 6:28:48 PM

Saturday, April 04, 2009 6:28:48 PM

Post# of 12137
Sage, just speculation about Quintiles, no news has ever been released. The reason I I'm using Quintiles would be in reference to Mr. Berry stating, CYRX was pursuing
the top 5 CRO's, This was part of the DEC, 2008 interview with TWST.
Quintiles, number 1, followed by Covance. Quest isn't even on the list of the top 5. I think Quest is big, but not Major in comparison to Quintiles or Covance.


If our product is best suited for international shipping, Quest looks to be a pimple on the asses of the aforementioned.



"Market Leaders Of the large, global contract research providers, Quintiles is the market leader, with 14% of the global market share; followed by Covance and PPD, holding 10% each. The five largest CROs have increased their market share and now hold 45% of the total market. "

Source: Courtesy of Indigo Research.


After looking at Quest home page and clinical shipments, and delving into the leaders in the CRO market, I concluded Quintiles and Covance are the most likely candidates for a Major roll-out, Not Quest, but I'm not counting Quest out, I think they'll be there to, at this point , Quest, IMO, doesn't have Major roll out status.
I don't know how you can with 3 locations in Europe, and a brand new location in India.



I think we have to distinguish between CRO and central labs.
Quest is considered a central lab. So if Mr. Berry is stating the top 5 CRO's as he mentioned in December of 2008 via TSWT, Than I'll continue to research and speculate that Quintiles or one of the other top 4 CRO's must be the major.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYRX News